Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma.

Masayuki Takeda,Yuichiro Ohe,Hidehito Horinouchi,Toyoaki Hida,Junichi Shimizu,Takashi Seto,Kaname Nosaki,Takumi Kishimoto, Itaru Miyashita,Masayuki Yamada,Yutaro Kaneko,Chikao Morimoto,Kazuhiko Nakagawa

Lung Cancer（2019）

引用 12|浏览30

暂无评分

摘要

•CD26 was found to be overexpressed in Malignant pleural mesothelioma cells, but not in benign mesothelial tissue.•YS110 is a recombinant humanized monoclonal antibody that binds with high affinity to human CD26.•YS110 showed promising antitumor efficacy and was generally well tolerated in Japanese patients with advanced MPM.

查看译文

关键词

CD26,Japanese,Malignant mesothelioma,Phase I,YS110

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要